AAAAAA

   
Results: 1-2 |
Results: 2
PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ORAL (PO) METHOXY-MORPHOLINO DOXORUBICIN (PNU-152243) ON A SINGLE INTERMITTENT SCHEDULE
Authors: SESSA C ZUCCHETTI M BAUER J NAEGELE H DINCALCI M GHIELMINI M ROSSI S VANDENBULCKE T PACCIARINI M DOMENIGONI L CAVALLI F
Citation: C. Sessa et al., PHASE-I CLINICAL AND PHARMACOKINETIC (PK) STUDY OF ORAL (PO) METHOXY-MORPHOLINO DOXORUBICIN (PNU-152243) ON A SINGLE INTERMITTENT SCHEDULE, Annals of oncology, 9, 1998, pp. 450-450
BROAD PHASE-II AND PHARMACOKINETIC STUDY OF METHOXY-MORPHOLINO DOXORUBICIN (FCE 23762-MMRDX) IN NON-SMALL-CELL LUNG-CANCER, RENAL-CANCER AND OTHER SOLID TUMOR PATIENTS
Authors: BAKKER M DROZ JP HANAUSKE AR VERWEIJ J VANOOSTEROM AT GROEN HJM PACCIARINI MA DOMENIGONI L VANWEISSENBRUCH F PIANEZZOLA E DEVRIES EGE
Citation: M. Bakker et al., BROAD PHASE-II AND PHARMACOKINETIC STUDY OF METHOXY-MORPHOLINO DOXORUBICIN (FCE 23762-MMRDX) IN NON-SMALL-CELL LUNG-CANCER, RENAL-CANCER AND OTHER SOLID TUMOR PATIENTS, British Journal of Cancer, 77(1), 1998, pp. 139-146
Risultati: 1-2 |